-
1
المؤلفون: Marcelo Fiorelli Alexandrino da Silva, Andressa Cristina Sposato Louzada, Marcelo Passos Teivelis, Nickolas Stabellini, Dafne Braga Diamante Leiderman, José Ribas Milanez de Campos, Edson Amaro Junior, Nelson Wolosker
المصدر: Sao Paulo Medical Journal, Issue: ahead, Published: 12 SEP 2022
Sao Paulo Medical Journal v.140 n.6 2022
São Paulo medical journal
Associação Paulista de Medicina
instacron:APMمصطلحات موضوعية: Adult, Male, Public health, Video-assisted thoracic surgery, General Medicine, Young Adult, Big data, Cross-Sectional Studies, Treatment Outcome, Humans, Hyperhidrosis, Oxybutynin, Female, Sympathectomy, Endoscopic thoracic sympathectomy, Brazil, Retrospective Studies
الوصف: BACKGROUND: Endoscopic thoracic sympathectomy is the definitive surgical treatment for hyperhidrosis and a nationwide study has suggested that cultural and socioeconomic factors play a role in the numbers of operations performed. Thus, there is a need to evaluate local data in order to understand the local epidemiology and trends in hyperhidrosis treatment. OBJECTIVE: To study the epidemiology of sympathectomy for treating hyperhidrosis in São Paulo, the largest city in Brazil. DESIGN AND SETTING: Population-based retrospective cross-sectional study. METHODS: Data on sympathectomies for treating hyperhidrosis between 2008 and 2018 were assessed from the database of the Municipal Health Department of São Paulo, Brazil. RESULTS: 65.29% of the patients were female, 66.2% were aged between 20 and 39 years and 37.59% had registered with addresses outside São Paulo. 1,216 procedures were performed in the city of São Paulo from 2008 to 2018, and 78.45% of them were in only two public hospitals. The number of procedures significantly declined over the years (P = 0.001). 71.63% of the procedures were associated with 2-3 days of hospital stay, only 78 intensive care unit days were billed and we did not observe any intra-hospital death. CONCLUSION: The profile of patients operated on in São Paulo (young women) is similar to that described in other populations. Sympathectomy is a very safe procedure, with no mortality in our series. There was a decreasing trend in the number of surgeries over the years.
وصف الملف: text/html
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a422be270c14da6e6bb27633f964f89Test
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-31802022005023204&lng=en&tlng=enTest -
2
المؤلفون: Elisabetta Fulgione, Stefano Caccavale, Caterina M. Giorgio, Ilenia D'Ambra, Riccardo Pampena, Giulia Briatico, Giuseppe Argenziano, Graziella Babino, Caterina Longo
المساهمون: Briatico, G., Pampena, R., Fulgione, E., Babino, G., Giorgio, C. M., D'Ambra, I., Caccavale, S., Longo, C., Argenziano, G.
مصطلحات موضوعية: Pediatrics, medicine.medical_specialty, Dermatology, Muscarinic Antagonists, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Quality of life, medicine, hyperhidrosis, oxybutynin, pharmacology, quality of life, Humans, Hyperhidrosis, hyperhidrosi, Oxybutynin, Adverse effect, Survival analysis, Retrospective Studies, business.industry, Retrospective cohort study, General Medicine, Dry mouth, humanities, Treatment Outcome, 030220 oncology & carcinogenesis, Cohort, Quality of Life, Mandelic Acids, medicine.symptom, business, medicine.drug
الوصف: Background Hyperhidrosis is a disorder of excessive sweating severely impacting on patient's quality of life (Qol). Several studies have been published about oral oxybutynin, but no studies focused on the achievement of complete clinical and Qol response. Objectives the aim of this study was to report our real-life experience with oral oxybutynin in patients with severe hyperhidrosis significantly affecting their Qol. Methods In this cohort retrospective study we enrolled, in a 3-year period, patients affected by severe hyperhidrosis with poor Qol, continuously treated with oral oxybutynin. Our outcome was the obtainment of complete clinical and Qol improvement. A systematic review of the literature was also performed reporting efficacy and safety of oral oxybutynin for primary hyperhidrosis. Results We enrolled 62 patients, of which 53 (85.5%) received a mean daily dose of 10 mg and 9 (15.5%) of 5 mg. Complete clinical response was achieved in 77.4% (48/62) of cases, while complete Qol improvement occurred in 51.6% (32/62) of cases. Adverse events were only reported as mild, with dry mouth being the most frequently observed (16.1%). Kaplan-Meier survival analysis highlighted that both median clinical and Qol complete responses were reached after 1 year of continuous therapy with oral oxybutynin. The main limitation of our study is the small number of patients enrolled. Conclusions Long-term therapy with oral oxybutynin for severe hyperhidrosis, continuously administered at a mean daily dosage of 5 to 10 mg, allowed the majority of our patients to reach both clinical and Qol complete improvement, without significant adverse events. This article is protected by copyright. All rights reserved.
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3354e73433d29c1e4153c0de7d2f2be4Test
https://hdl.handle.net/11380/1236606Test -
3
المؤلفون: Maida Zonić-Imamović, Mirza Imamović, Semir Imamović, Renata Hodžić, Azra Delalić, Amela Čičkušić
المصدر: Acta Medica Academica. 48:271-277
مصطلحات موضوعية: Male, medicine.medical_specialty, Multiple Sclerosis, medicine.drug_class, Urology, Cholinergic Antagonists, law.invention, Randomized controlled trial, Quality of life, law, Surveys and Questionnaires, Statistical significance, medicine, Anticholinergic, Humans, Oxybutynin, Urinary bladder, Urinary Bladder, Overactive, business.industry, Multiple sclerosis, General Medicine, Middle Aged, medicine.disease, Treatment Outcome, medicine.anatomical_structure, Overactive bladder, Quality of Life, Transcutaneous Electric Nerve Stimulation, Mandelic Acids, Female, Tibial Nerve, business, medicine.drug
الوصف: Objective. The purpose of this study was to evaluate the efficiency of the anticholinergic therapy with oxybutynin and the effects of daily transcutaneous tibial nerve stimulation (TTNS) on the quality of life of patients with an overactive bladder (OAB) and multiple sclerosis (MS). Patients and Methods . The study was designed as a randomized controlled trial. The patients who suffer from MS underwent urodynamic tests which showed that they had an OAB. The tests used to assess symptoms and quality of life were Overactive Bladder Questionnaires (OAB-q) SF. Patients were divided into 2 groups of 30 patients each. The first group received a 5 mg oxybutynin tablet twice a day for 3 months and the second group had TTNS every day for 3 months. Results . The anticholinergic therapy showed a statistically significant improvement in all symptoms and quality of life (P
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::863072612dfbf3e617c3312911ad8fe2Test
https://doi.org/10.5644/ama2006-124.267Test -
4
المصدر: Dermatologic therapyREFERENCES. 34(1)
مصطلحات موضوعية: medicine.medical_specialty, Dermatology, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Medicine, Humans, Hyperhidrosis, Prospective Studies, Craniofacial, Oxybutynin, Adverse effect, business.industry, General Medicine, Trunk, medicine.anatomical_structure, Treatment Outcome, 030220 oncology & carcinogenesis, Scalp, Cohort, Axilla, Mandelic Acids, medicine.symptom, business, Craniofacial hyperhidrosis, medicine.drug
الوصف: The term craniofacial hyperhidrosis (HH) refers to HH that affects the face and/or scalp. Few studies have focused on this specific location, and even fewer distinguish between the two areas. Our study aims are to describe the clinical characteristics of patients with craniofacial HH, specifying whether the condition affects the scalp, face or both, and to compare these cases with those recorded at other locations. As secondary objectives, we determine the effectiveness and adverse effects of oral oxybutynin (OOx), and assess patients' adherence to treatment. This prospective observational study was carried out with respect to the period 2007-2019. All patients diagnosed with HH of the scalp and/or face and who were treated with OOx at our HH unit were included in the study group. Of 292 patients treated with OOx, 97 (33.2%) had craniofacial HH. Of these, 4 (4.1%) presented HH exclusively on the scalp, 56 (57.7%) exclusively on the face and 37 (38.1%) in both locations. The patients in the latter category (compared with those with exclusively facial HH) were significantly older than the others, had a later onset of HH, a greater frequency of secondary HH, less simultaneous involvement of the classical areas of primary focal HH (the palms, soles, and armpits) and greater generalized HH and of the trunk. No significant differences were observed between the three locations (face, scalp, or both) regarding the efficacy and side effects of OOx. The patients with exclusively facial HH presented greater adherence to treatment.
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19c39a9f966acbb821d5705e4b93a72dTest
https://pubmed.ncbi.nlm.nih.gov/33301207Test -
5
المؤلفون: Fernanda Ferrari, Vanessa Barreto Rocha, Ada Regina Trindade Almeida, Maria Victoria Suarez Restrepo
المصدر: Dermatologic Therapy. 33
مصطلحات موضوعية: Adult, Male, Pediatrics, medicine.medical_specialty, Adolescent, Dermatology, Demographic data, Young Adult, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Disease severity, Quality of life, medicine, Humans, Hyperhidrosis, Longitudinal Studies, Family history, Child, Oxybutynin, Aged, business.industry, General Medicine, Middle Aged, Trunk, Treatment Outcome, 030220 oncology & carcinogenesis, Quality of Life, Mandelic Acids, Female, medicine.symptom, business, Life study, medicine.drug
الوصف: Hyperhidrosis is a condition of excessive sweating beyond physiological parameters that can seriously impair quality of life. This study aims to evaluate the oral oxybutynin effectiveness in hyperhidrosis, besides its tolerance and safety. In a real-life long-term study, 30 patients with primary hyperhidrosis and Hyperhidrosis Disease Severity Scale (HDSS) with score of at least two were submitted to a questionnaire to assess demographic data, HDSS and side effects of oxybutynin. Most patients were women (n = 23, 76.7%), median age was 40 years (range 12-70, SD 17.5) and 17(56.7%) had family history of hyperhidrosis. The most common hyperhidrosis form was axillary (n = 15, 50.0%), followed by palmoplantar (n = 8, 26.7%), cranio-facial (n = 11, 36.7%) and trunk (n = 5, 16.7%). Median duration of treatment was 2.4 years (range 1-6 years, SD 1.3). Thus, all patients used oxybutynin for at least 1 year, 30% for 2 years, 20% 3 years, 17% 4 years, and 3% 6 years. There was a significant improvement in HDSS score of patients (P < .001). This real life study suggests that oxybutynin is effective and safe for treatment of hyperhidrosis, both in children and adults, with mild and tolerable side effects, with significant improvement in HDSS.
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0fc98e1c7ea71a8d328582860cc02086Test
https://doi.org/10.1111/dth.14344Test -
6
المصدر: Dermatologic Therapy. 33
مصطلحات موضوعية: Adult, medicine.medical_specialty, medicine.drug_class, Treatment adherence, Muscarinic Antagonists, Dermatology, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Epidemiology, Anticholinergic, Humans, Hyperhidrosis, Medicine, Prospective Studies, Treatment Failure, Prospective cohort study, Adverse effect, Oxybutynin, Glycopyrrolate, business.industry, General Medicine, Treatment Adherence and Compliance, Treatment Outcome, 030220 oncology & carcinogenesis, Mandelic Acids, Female, medicine.symptom, business, medicine.drug
الوصف: Oral anticholinergics such as oxybutynin (OOx) and glycopyrrolate (OGly) are frequently used in the management of hyperhidrosis. Although OOx is considered currently the anticholinergic drug of first choice, OGly is a safe and effective alternative if OOx fails. The aim of this study was to identify the main variables associated with treatment adherence by patients receiving OGly, for whom previous treatment with OOx had failed. A prospective study was conducted of patients with hyperhidrosis receiving treatment with OGly in the period 2012 to 2019. Epidemiological variables, treatment details, effectiveness and adverse effects were recorded. A total of 58 patients (41 women), with a mean age of 35.9 years, were included in the study. The median follow-up period was 32 months. At 3 months, 70.7% of the patients had responded to treatment (excellent response: 75.6%), and adverse effects were reported by 70.7%. At 12 months, 53.4% had responded (excellent response: 74.2%), with adverse effects in 70.9%. The variables associated with poorer adherence were affected areas: palms of the hands, soles of the feet and armpits. The only variable associated with greater adherence was the generalized presence of hyperhidrosis. Our results provide valuable insights into the outcomes achieved when OGly is used to treat hyperhidrosis.
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b12981ca9b3eb2881953e7dc944b7edTest
https://doi.org/10.1111/dth.14210Test -
7
المؤلفون: Javier Del Boz Gonzalez, José Francisco Millán-Cayetano, Magdalena de Troya Martín, Diego Rodríguez Barón
المصدر: Dermatologic Therapy. 33
مصطلحات موضوعية: medicine.medical_specialty, Good control, Muscarinic Antagonists, Dermatology, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Epidemiology, medicine, Humans, Hyperhidrosis, Oxybutynin, Retrospective Studies, business.industry, Retrospective cohort study, General Medicine, Treatment efficacy, Alternative treatment, Treatment Outcome, 030220 oncology & carcinogenesis, Mandelic Acids, medicine.symptom, business, Prolonged treatment, medicine.drug
الوصف: Oral oxybutynin (OOx) is an effective and safe treatment for the treatment of hyperhidrosis (HH). However, in some patients a loss of efficacy during prolonged treatment has been observed. Analysis of these cases could enable us to identify patients susceptible to OOx tolerance. An alternative treatment might then be considered. To assess tolerance to OOx in the treatment of HH. Secondarily, to assess epidemiological data and the duration of efficacy, together with the probable causes of any loss in this respect. Retrospective study of patients who started treatment with OOx for HH during the period 2007 to 2017 and who either abandoned this treatment due to loss of efficacy or needed higher daily doses to maintain the initial efficacy. Epidemiological data were collected, the duration of the efficacy of OOx was recorded and the possible causes of loss of efficacy were considered. The development of tolerance was suspected in 18 patients (8.5%) of the 211 who had previously responded to OOx. Thirteen patients abandoned OOx due to its lack of efficacy and five had to increase the dose in order to maintain efficacy. In seven patients, tolerance to the drug appeared in the first year of treatment, while in the remaining 11, the tolerance appeared later. Most patients achieved and maintained good control of HH with long-term OOx. However, in some cases the efficacy of the drug decreases. The study analysis did not produce findings enabling us to predict a loss of treatment efficacy.
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba293399d23dab1fa5c0e62e791bcdf8Test
https://doi.org/10.1111/dth.14197Test -
8
المؤلفون: Fernando Garcia-Souto, Javier del Boz, Juan Polo-Padillo
المصدر: Dermatologic therapyREFERENCES. 33(6)
مصطلحات موضوعية: Study groups, Treatment protocol, Administration, Oral, Dermatology, Muscarinic Antagonists, Treatment failure, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, medicine, Humans, Hyperhidrosis, Prospective Studies, Prospective cohort study, Oxybutynin, Adverse effect, Glycopyrrolate, business.industry, Temperature, General Medicine, Treatment Outcome, 030220 oncology & carcinogenesis, Anesthesia, Seasons, medicine.symptom, business, medicine.drug
الوصف: The condition of most patients with hyperhidrosis (HH) is known to worsen with increased temperature. However, most prior studies of oral glycopyrrolate (OGly) for the treatment of HH have assumed a stable treatment protocol, without taking into account seasonal variations in temperature. The main aim of this study is to evaluate the outcomes derived from performing a seasonal adjustment of the dose of OGly for patients with HH. A prospective study of patients who began OGly for HH, and maintained treatment for at least 1 year, was performed. All patients had experienced treatment failure with oral oxybutynin. All were recommended to vary the dose of medication according to the time of year. Of the 35 patients included in the study, 20 (57.14%) varied the dose. Those with palmar and plantar HH had a greater propensity to do so. The patients who varied the dose according to the time of year were significantly more likely to report an "Excellent" response after 12 months of treatment. The frequency of adverse effects was 71.4% with no significant differences among the study groups. However, there was a significantly higher proportion of adverse effects other than oral xerosis in the group that did not vary the dose.
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ca2ca4da320bb3a4e91eec5fdc117f8Test
https://pubmed.ncbi.nlm.nih.gov/32860330Test -
9
المؤلفون: Wendy Tucker, Mark Yarchoan, Thomas J. Smith
المصدر: J Palliat Med
مصطلحات موضوعية: medicine.medical_specialty, business.industry, Extramural, Treatment outcome, MEDLINE, General Medicine, Anesthesiology and Pain Medicine, Text mining, Internal medicine, medicine, business, Oxybutynin, Letters to the Editor, General Nursing, medicine.drug
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::092cef8b57b0e796d38a01be85236171Test
https://europepmc.org/articles/PMC6882448Test/ -
10
المؤلفون: Juliana Maria Fukuda, Nelson Wolosker, Lucas Lembrança Pinheiro, Marcelo Passos Teivelis, José Ribas Milanez de Campos, Andrea Yasbek Monteiro Varella, Cynthia de Almeida Mendes, Paulo Kauffman
المصدر: Revista da Associação Médica Brasileira v.64 n.2 2018
Revista da Associação Médica Brasileira
Associação Médica Brasileira (AMB)
instacron:AMB
Revista da Associação Médica Brasileira, Vol 64, Iss 2, Pp 127-132
Repositório Institucional da USP (Biblioteca Digital da Produção Intelectual)
Universidade de São Paulo (USP)
instacron:USP
Revista da Associação Médica Brasileira, Volume: 64, Issue: 2, Pages: 127-132, Published: FEB 2018مصطلحات موضوعية: Male, Antifungal Agents, Glândulas Apócrinas, Administration, Topical, 030207 dermatology & venereal diseases, 0302 clinical medicine, Axillary region, Quality of life, Surveys and Questionnaires, Sweat Gland Diseases, Child, Clinical treatment, lcsh:R5-920, Hyperhidrosis, Clindamycin, General Medicine, Middle Aged, Anti-Bacterial Agents, Treatment Outcome, Apocrine Glands, Child, Preschool, 030220 oncology & carcinogenesis, SUOR, Drug Therapy, Combination, Female, medicine.symptom, Antagonistas Muscarínicos, lcsh:Medicine (General), After treatment, medicine.drug, Adult, medicine.medical_specialty, Adolescent, Hiperidrose, Doenças das Glândulas Sudoríparas, Sweating, Muscarinic Antagonists, Soaps, Young Adult, 03 medical and health sciences, Keratolytic Agents, medicine, Humans, In patient, Oxybutynin, Retrospective Studies, business.industry, Dermatology, Topical agents, Odorants, Quality of Life, Mandelic Acids, business
الوصف: Summary Introduction: The association of osmidrosis and hyperhidrosis often causes emotional and social problems that may impair the patients' quality of life. The purpose of our study was to analyze the therapeutic results of oxybutynin and topical agents in 89 patients with both osmidrosis and hyperhidrosis. Method: We conducted an observational study at two specialized centers of hyperhidrosis between April 2007 and August 2013. Eighty-nine (89) patients with both osmidrosis and hyperhidrosis were treated with oxybutynin and topical agents. Patients were evaluated before treatment and at 3 and 6 weeks after treatment started, by using the Quality of Life Questionnaire and the Sweating Evolution Scale. Results: Before treatment, 98% of the patients presented with poor or very poor quality of life. After six weeks of treatment, 70% stated their quality of life as being slightly better or much better (p
وصف الملف: text/html
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85244cff4dbe868911779da4b6eaf7f0Test
https://doi.org/10.1590/1806-9282.64.02.127Test
